D. Kirpotin

发表

Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development.

John W. Park, D. Drummond, C. Noble, 2008, Journal of pharmaceutical sciences.

Assembly of nucleic acid-lipid nanoparticles from aqueous-organic monophases.

J. Marks, D. Drummond, M. Hayes, 2006, Biochimica et biophysica acta.

Cationic Liposomes Coated with Polyethylene Glycol As Carriers for Oligonucleotides*

John W. Park, D. Papahadjopoulos, M. Woodle, 1998, The Journal of Biological Chemistry.

Immunoliposomes for cancer treatment.

John W. Park, C. Benz, D. Kirpotin, 1997, Advances in pharmacology.

Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.

U. Nielsen, C. Benz, John W. Park, 2006, Cancer research.

Convection-enhanced delivery of targeted quantum dot-immunoliposome hybrid nanoparticles to intracranial brain tumor models.

F. Chen, C. James, John W. Park, 2013, Nanomedicine.

Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo.

C. Mamot, John W. Park, D. Drummond, 2005, Cancer research.

Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors.

D. Papahadjopoulos, D. Drummond, D. Kirpotin, 1999, Pharmacological reviews.

Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.

Ulrik B Nielsen, U. Nielsen, J. Baselga, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs.

W. Kamoun, Z. Huang, D. Drummond, 2019, Journal of controlled release : official journal of the Controlled Release Society.

Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer

Thomas, Cynthia, B. Hendriks, 2017 .

Companion Diagnostic 64Cu-Liposome Positron Emission Tomography Enables Characterization of Drug Delivery to Tumors and Predicts Response to Cancer Nanomedicines

B. Hendriks, J. Fitzgerald, Helen Lee, 2018, Theranostics.

Extensive Distribution of Liposomes in Rodent Brains and Brain Tumors Following Convection-Enhanced Delivery

M. Berger, C. Mamot, John W. Park, 2004, Journal of Neuro-Oncology.

In vivo Multiple Anticancer Drugs Immunoliposomes Significantly Enhance the Efficacy of Targeted − Epidermal Growth Factor Receptor

C. Mamot, John W. Park, D. Drummond, 2005 .

Epidermal Growth Factor Receptor (EGFR)-targeted Immunoliposomes Mediate Specific and Efficient Drug Delivery to EGFR- and EGFRvIII-overexpressing Tumor Cells1

C. Mamot, John W. Park, J. Marks, 2003 .

Epidermal Growth Factor Receptor ( EGFR )-targeted Immunoliposomes Mediate Specific and Efficient Drug Delivery to EGFR-and EGFRvIII-overexpressing Tumor Cells 1

C. Mamot, John W. Park, J. Marks, 2003 .

Development of a highly stable and targetable nanoliposomal formulation of topotecan.

Ceirin M. Connolly-Ingram, C. Benz, B. Hann, 2010, Journal of controlled release : official journal of the Controlled Release Society.

Pharmacokinetics, tumor accumulation and antitumor activity of nanoliposomal irinotecan following systemic treatment of intracranial tumors.

M. Berger, John W. Park, D. Drummond, 2014, Nanomedicine.

Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy.

M. Berger, John W. Park, D. Drummond, 2006, Cancer research.

Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts.

John W. Park, T. Kawaguchi, D. Drummond, 2007, Neuro-oncology.

Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine

C. Benz, John W. Park, J. Marks, 2009, Cancer Chemotherapy and Pharmacology.

Comprehensive optimization of a single-chain variable domain antibody fragment as a targeting ligand for a cytotoxic nanoparticle

U. Nielsen, A. Lugovskoy, Y. Jiao, 2015, mAbs.

Intraliposomal Trapping Agents for Improving In Vivo Liposomal Drug Formulation Stability

John W. Park, D. Drummond, C. Noble, 2006, Liposome Technology.

Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function.

R. Neve, U. Nielsen, C. Benz, 2001, Biochemical and biophysical research communications.

A novel assay for monitoring internalization of nanocarrier coupled antibodies

U. Nielsen, J. Marks, D. Drummond, 2006, BMC Immunology.

Distribution of Liposomes into Brain and Rat Brain Tumor Models by Convection-Enhanced Delivery Monitored with Magnetic Resonance Imaging

M. Berger, M. Wendland, C. Mamot, 2004, Cancer Research.

High-performance ion-exchange chromatography of oligoribonucleotides using linear and hyperbolic salt gradients.

A. Wolfson, D. Kirpotin, Tsygankov AYu, 1989, Journal of chromatography.

Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models

W. Kamoun, J. Marks, A. Lugovskoy, 2019, Nature Biomedical Engineering.

Development of disulfide-stabilized Fabs for targeting of antibody-directed nanotherapeutics

A. Lugovskoy, D. Drummond, D. Kirpotin, 2022, mAbs.

Improving the developability of an anti-EphA2 single-chain variable fragment for nanoparticle targeting

J. Marks, A. Lugovskoy, Y. Jiao, 2017, mAbs.

Convection-enhanced delivery of liposomal doxorubicin in intracranial brain tumor xenografts

M. Berger, John W. Park, T. Kawaguchi, 2006, Targeted Oncology.

64 Cu-MM-302 Positron Emission Tomography Quanti ﬁ es Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer

B. Hendriks, A. Shields, P. LoRusso, 2017 .

Improved Pharmacokinetics and Efficacy of a Highly Stable Nanoliposomal Vinorelbine

John W. Park, D. Drummond, C. Noble, 2009, Journal of Pharmacology and Experimental Therapeutics.

Anti‐HER2 Immunoliposomes for Targeted Drug Delivery

C. Benz, D. Papahadjopoulos, R. Shalaby, 1999, Annals of the New York Academy of Sciences.

Convection-enhanced delivery of Ls-TPT enables an effective , continuous , low-dose chemotherapy against malignant glioma xenograft model 1

M. Berger, John W. Park, D. Drummond, 2006 .

Magnetic targeting of a therapeutic antibody using magnetotropic microspheres of the interpolyelectrolyte coacervation complex.

F. Emmrich, R. Kinne, D. Kirpotin, 1993 .

Sterically Stabilized Immunoliposomes: Formulations for Delivery of Drugs and Genes to Tumor Cells in Vivo

C. Benz, John W. Park, D. Papahadjopoulos, 1998 .

Liposome-based approaches to overcome anticancer drug resistance.

C. Mamot, John W. Park, D. Drummond, 2003, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Synthesis and evaluation of colloidal magnetic iron oxides for the site-specific radiofrequency-induced hyperthermia of cancer

P. Bunn, D. Kirpotin, Paul A. Bunn, 1993 .

Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy.

John W. Park, D. Drummond, C. Noble, 2006, Cancer research.

Anti-HER2 immunoliposomes for targeted therapy of human tumors.

C. Benz, D. Papahadjopoulos, D. Kirpotin, 1997, Cancer letters.

Clinical development of histone deacetylase inhibitors as anticancer agents.

C. Benz, G. Scott, D. Drummond, 2005, Annual review of pharmacology and toxicology.

Genospheres: self-assembling nucleic acid-lipid nanoparticles suitable for targeted gene delivery

C. Benz, John W. Park, J. Marks, 2006, Gene Therapy.

Targeting EphA2 in Bladder Cancer Using a Novel Antibody-Directed Nanotherapeutic

C. Morrison, M. Mino‐Kenudson, W. Bshara, 2018, Pharmaceutics.

Canine spontaneous glioma: a translational model system for convection-enhanced delivery.

M. Berger, John W. Park, D. Drummond, 2010, Neuro-oncology.

Mapping Tumor Epitope Space by Direct Selection of Single-Chain Fv Antibody Libraries on Prostate Cancer Cells

Matthew R Cooperberg, Bin Liu, M. Cooperberg, 2004, Cancer Research.

Drug Stability and Minimized Acid-/Drug-Catalyzed Phospholipid Degradation in Liposomal Irinotecan.

Z. Huang, D. Drummond, C. Noble, 2022, Journal of pharmaceutical sciences.

Development of ligand-targeted liposomes for cancer therapy

C. Benz, C. Mamot, John W. Park, 2004, Expert opinion on therapeutic targets.

Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model.

M. Berger, John W. Park, D. Drummond, 2006, Neuro-oncology.

Liposome targeting to tumors using vitamin and growth factor receptors.

C. Benz, D. Drummond, D. Kirpotin, 2000, Vitamins and hormones.

Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.

Udo Greiser, C. Mamot, John W. Park, 2003, Cancer research.

64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer

Karen Campbell, Ian Krop, Barry A Siegel, 2017, Clinical Cancer Research.

A gradient-loadable (64)Cu-chelator for quantifying tumor deposition kinetics of nanoliposomal therapeutics by positron emission tomography.

B. Hendriks, D. Jaffray, J. Hoppin, 2015, Nanomedicine : nanotechnology, biology, and medicine.

Building and characterizing antibody-targeted lipidic nanotherapeutics.

Yu Zhou, Ulrik B Nielsen, Zhaohua Huang, 2012, Methods in enzymology.

Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo.

Kevin C Weng, F. Chen, Donghui Wang, 2008, Nano letters.

Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells

C. Benz, B. Liu, J. Marks, 2007, Molecular Cancer Therapeutics.

Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells.

Yu Zhou, G. Adams, J. Marks, 2007, Journal of molecular biology.

Preclinical Manufacture of Anti‐HER2 Liposome‐Inserting, scFv‐PEG‐Lipid Conjugate. 2. Conjugate Micelle Identity, Purity, Stability, and Potency Analysis

John W. Park, J. Marks, D. Drummond, 2008, Biotechnology progress.

Preclinical Manufacture of an Anti‐HER2 scFv‐PEG‐DSPE, Liposome‐Inserting Conjugate. 1. Gram‐Scale Production and Purification

Jianwei Zhu, Jianwei Zhu, John W. Park, 2008, Biotechnology progress.

Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis.

Ulrik B Nielsen, U. Nielsen, C. Benz, 2002, Biochimica et biophysica acta.

Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.

John W. Park, C. Benz, P. Carter, 1997, Biochemistry.

Enhanced Pharmacodynamic and Antitumor Properties of a Histone Deacetylase Inhibitor Encapsulated in Liposomes or ErbB2-Targeted Immunoliposomes

C. Benz, Donghui Wang, G. Scott, 2005, Clinical Cancer Research.

Liposomal Drug Delivery Systems for Cancer Therapy

C. Benz, John W. Park, D. Drummond, 2004 .

Anti-HER 2 Immunoliposomes : Enhanced Efficacy Attributable to Targeted Delivery 1

U. Nielsen, J. Baselga, C. Benz, 2002 .

Tumor targeting using anti-her2 immunoliposomes.

U. Nielsen, C. Benz, John W. Park, 2001, Journal of controlled release : official journal of the Controlled Release Society.

CHAPTER 4.7 – Targeting of sterically stabilized liposomes to cancers overexpressing HER2/neu proto-oncogene

C. Benz, John W. Park, D. Papahadjopoulos, 1998 .

Targeting of Drugs to Solid Tumors Using Anti-Her2 Immunoliposomes

C. Benz, John W. Park, D. Papahadjopoulos, 1998 .

Targeting of Liposomes to Solid Tumors: The Case of Sterically Stabilized Anti-Her2 Immunoliposomes

C. Benz, John W. Park, D. Papahadjopoulos, 1997 .

Liposomes with detachable polymer coating: destabilization and fusion of dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface‐grafted poly(ethylene glycol)

Samuel Zalipsky, D. Papahadjopoulos, D. Kirpotin, 1996, FEBS letters.

Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts.

M. Prados, C. James, John W. Park, 2011, Neuro-oncology.

Emerging antibody-based HER2 (ErbB-2/neu) therapeutics.

C. Benz, D. Kirpotin, K. Hong, 2000, Breast disease.

Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies.

B. Liu, Lan Huang, J. Marks, 2007, Molecular immunology.

Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts.

M. Berger, M. Prados, C. James, 2013, Neuro-oncology.

Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging: laboratory investigation.

Yoji Yamashita, Mitchel S Berger, M. Berger, 2008, Journal of neurosurgery.

Physical Chemistry and in Vivo Tissue Heating Properties of Colloidal Magnetic Iron Oxides with Increased Power Absorption Rates

P. Bunn, D. Kirpotin, Daniel C. F. Chan, 1997 .

Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies

B. Liu, D. Drummond, D. Kirpotin, 2008, Molecular Cancer Therapeutics.

Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models

W. Kamoun, J. Marks, A. Lugovskoy, 2019, Nature Biomedical Engineering.

Increased target specificity of anti-HER2 genospheres by modification of surface charge and degree of PEGylation.

C. Benz, J. Cohen, J. Marks, 2006, Molecular pharmaceutics.

Abstract P3-14-09: Preclinical Safety and Activity of MM-302, a HER2-Targeted Liposomal Doxorubicin Designed To Have an Improved Safety and Efficacy Profile over Approved Anthracyclines

C. Benz, B. Hendriks, John W. Park, 2010 .

Development of novel liposomal and receptor tyrosine kinase-targeted immunoliposomal vinorelbine formulations with improved drug retention

C. Mamot, John W. Park, J. Marks, 2005 .

Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.

C. Mamot, John W. Park, J. Marks, 2003, Cancer research.

Liposomal Drug Delivery Systems for Cancer Therapy

C. Benz, John W. Park, D. Drummond, 2004 .

Abstract 750: Nanoliposomal targeting of Ephrin receptor A2 (EphA2): Clinical translation:

W. Kamoun, J. Marks, A. Lugovskoy, 2016 .

Model fossilization of polymer microstructures and the problem of the oldest fossils

D. Kirpotin, K. Gladilin, A. F. Orlovskii, 1986, Origins of life and evolution of the biosphere.

Abstract 5771: Targeting EphA2 in bladder cancer using a novel antibody-directed nanotherapeutic

C. Morrison, W. Bshara, W. Kamoun, 2018, Experimental and Molecular Therapeutics.